Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Launched by HOSPITAL MOINHOS DE VENTO · Mar 22, 2022

Keywords

ClinConnect Summary

The Onco-Genomas Brasil trial is studying breast and prostate cancer to better understand the genetic makeup of these diseases in Brazilian patients. The goal is to collect detailed information about the tumors and the patients' genetic backgrounds to help improve cancer treatment and care within the Brazilian public health system. Researchers are looking for patients who meet specific criteria: for breast cancer, women aged 18 and older with certain types of breast tumors, and for prostate cancer, men aged 18 and older with advanced prostate cancer. Participants will need to provide written consent to join the study.

If you qualify for this trial, you can expect to undergo tests that analyze your tumor's genetic information and your own DNA. This could help researchers learn more about how these cancers develop and respond to treatment, ultimately leading to more personalized care for future patients. It's important to note that participants must have available tumor samples and be able to provide blood samples for these tests. Your involvement could play a vital role in advancing cancer research and improving health outcomes for others in the Brazilian community.

Gender

ALL

Eligibility criteria

• Inclusion criteria for breast cancer patients (Arm 1):
• • Women aged ≥ 18 years;
• • Brazilian nationality;
• • After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors \<1% and no overexpression of HER2);
• • Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition;
• • HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthracycline option consisting of taxane (docetaxel or paclitaxel) combined with carboplatin and trastuzumab;
• • Triple-negative patients: must undergo neoadjuvant chemotherapy without immunotherapy in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel) with/ without platins (carboplatin ou cisplatin) or a regimen without anthracycline (taxane with/without platins)
• • Patients must provide written informed consent prior to inclusion
• Inclusion criteria for patients with prostate cancer (Arm 2):
• • Men aged ≥ 18 years;
• • Confirmed histological diagnosis of prostate adenocarcinoma;
• • AJCC 8th edition clinical stage IV;
• • Patients must provide written informed consent.
• Exclusion criteria for Arms 1 and 2:
• • No available paraffin-embedded tumor tissue for genomic analysis;
• • Inability to collect blood for genomic evaluation.